Ranibizumab in Myopic Choroidal Neovascularization: The 12-Month Results from the REPAIR Study

The REPAIR study was a phase II, prospective, multicenter, industry-sponsored study (clinical trial registration: http://clinicaltrials.gov/; identifier: NCT01037348) of intravitreal ranibizumab in myopic choroidal neovascularization (CNV). The purpose was to collect data in a validated robust manner to describe the visual, anatomic, and patient-reported outcome measures in a large cohort of treatment-naïve patients with myopic CNV after intravitreal ranibizumab as primary and first-line therapy using a pragmatic retreatment algorithm. Detailed methodology has previously been reported. Briefly, patients were eligible if they had subfoveal or juxtafoveal CNV secondary to pathologic myopia and (Read more...)

Full Story →